Remove 2004 Remove Pharma Remove Prescription
article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

Despite a slew of prescription options and widespread advertising pushes, most patients are sticking with over-the-counter (OTC) remedies rather than trying new preventive medications, according to Phreesia Life Sciences’ survey results collected from more than 4,000 patients checking in for their doctors’ appointments in July 2021.

article thumbnail

A Pharma Marketing Pioneer, Sander Flaum, Passed Away

Contrarian Sales Techniques

He then launched Flaum Navigators in 2004, which was a consultancy that sought to help clients embrace innovation in medical sales and marketing. His most recent column, "For a Pop in Prescriptions," was featured in the December 2022 edition of Med Ad News. He earned his undergraduate and MBA degrees from The Ohio State University.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

Along their journey, specialty pharma patients interact with a series of siloed institutions: clinics, specialty pharmacies, copay program vendors, patient assistance programs, nurses, etc. To diagnose the problem facing specialty pharma, a brief history lesson is in order. Visa’s attempted $5.3 Many are still making the transition.

article thumbnail

The Dark Side of KOL Relationship

Contrarian Sales Techniques

While building and maintaining relationships with key opinion leaders (KOLs) and thought leaders is an essential part of a pharmaceutical sales representative's job, there have been cases where reps have misused their relationship with KOLs to influence prescriptions. Another example is the case of Purdue Pharma and the opioid crisis.

Ethics 52
article thumbnail

Uri Goren

Cadensee

When he was going through his cancer, he died in 2004. So, do you listen to them at the point when a pharma company decides what drug it needs to make? We are cautious in pharma because we have regulations and the boundaries, and their risks are higher. So, I myself, was a care giver for my father. And that's how it started.